One year ago, an array of highly skilled and specialized nurses helped Cleveland Clinic became the first healthcare organization in the U.S. to deliver a baby from a deceased-donor uterine transplant.
For the second time in its clinical trial, a Cleveland Clinic patient has given birth after receiving a transplanted uterus from a deceased donor. In this article, Ob/Gyns on the transplant team provide a closer look at the transplant procedure and fertility treatments provided to a patient with MRKH syndrome.
Findings from Cleveland Clinic’s experience can inform other transplant centers of relative costs and aid in decision-making regarding referral of patients with comorbidities like hepatopulmonary syndrome.
In uterus transplant, imaging plays an important role in recipient and donor selection, recovery and pregnancy. In this article, Myra Feldman, MD, Medical Director of Ultrasound, discusses what to look for at each point in the process.
Investigators at Cleveland Clinic entered a new phase of cystic fibrosis research following the renewal of a prestigious consortium grant and designation as the sole biorepository site and coordinating center for 15 participating institutions.
There are several measures that can be taken in order to reduce risk for lung transplant patients during the COVID-19 pandemic.
A new JACC statement makes the case for earlier referral of patients with advanced heart failure. Our experts review the recommendations and the rationale behind them.
Cleveland Clinic has developed a protocol centered on housing transplant patients and donors in designated COVID-free units.
Cleveland Clinic Cancer Center researchers evaluating bortezomib as a possible prophylaxis for graft-versus-host disease (GVHD) in high-risk multiple myeloma unexpectedly found high rates of acute and chronic GVHD in patients participating in the small phase I clinical trial, forcing its discontinuation.
Hypertrophic cardiomyopathy is the most common cause of sudden cardiac death from ventricular arrhythmias in young people. In this case study, LCSD is an effective anti-arrhythmic therapy in a 15 year-old patient with hypertrophic cardiomyopathy at risk for sudden arrhythmic death.